Women's health
Ethinyl estradiol + norethindrone
Estrogen + Progestin
Other names: Alyacen, Aranelle, Aurovela, Balziva, Blisovi, Briellyn
Wait
24 hours
after the first dose
The FAA's MedGuide lists ethinyl estradiol + norethindrone (Alyacen, Aranelle, Aurovela, Balziva, Blisovi, Briellyn, Cyclafem, Generess, Junel, Kaitlib, Larin, Layolis, Leena, Lo Loestrin Fe, Loestrin, Microgestin, Minastrin, Necon, Nortrel, Nylia, Ortho-Novum, Pirmella, Tilia, Vyfemla, Wymzya) as allowed, for acne, contraception or menstrual bleeding, with a wait of 24 hours after the first dose and none after later doses or after the final dose, used as prescribed.
Track your medicationsMore detail: ethinyl estradiol + norethindroneThe rest of Crosscheck's reading, in plain wordsOpen
The MedGuide defines allowed as acceptable for use while performing flight or safety-related duties, provided the condition is stable/aeromedically acceptable and no adverse side effects are present, and says wait times are not determined solely by the medication: an extended observation period may be required to verify clinical stability of the condition.
- 24 hours after the first dose: ground observation
Show the FAA's words: ethinyl estradiol + norethindroneThe official FAA wording: three passages, each with its document and dateOpen
Generic: ethinyl estradiol + norethindrone
Brand Name: Alyacen; Alyacen; Aranelle; Aurovela; Balziva; Blisovi; Briellyn; Cyclafem; Generess; Junel; Kaitlib; Larin; Layolis; Leena; Lo Loestrin Fe; Loestrin; Microgestin; Minastrin; Necon; Nortrel; Nylia; Ortho-Novum; Pirmella; Tilia; Vyfemla; Wymzya
Drug Class: Estrogen + Progestin
Underlying Condition: Acne; Contraception; Menstrual bleeding
Use: ALLOW
INITIAL Wait Time (after first dose): 24 hours
SUBSEQUENT Dose Wait Time (after each dose): None
DISCONTINUATION Wait Time (after final dose): None
Frequency Use Limit: As prescribed
ALLOWED: The medication is acceptable for use while performing flight or safety-related duties, provided the condition is stable/aeromedically acceptable and no adverse side effects are present.
Underlying Condition: Evaluating medication use requires considering the impact of safety of flight from both the medication and underlying condition. Wait times are not determined solely by the medication; an extended observation period may be required to verify clinical stability of the condition.